


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 19452A-000320US
Client Reference No.: SD99-012-3MI

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



On September 2, 2004

TOWNSEND and TOWNSEND and CREECH LLP

By: Stephanie J. Whitehurst

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MARTH and ELLIES

Application No.: 09/856,391

Filed: January 7, 2002

For: USE OF CORE 2 GLCNAC
TRANSFERASE INHIBITORS IN
TREATING INFLAMMATION

Customer No.: 20350

Confirmation No.: 7913

Examiner: Zara, Jane J.

Art Unit: 1635

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.


Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Kevin Bastian
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
KLB:mtd



Substitute for Form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/856,391	
			Filing Date	January 7, 2002	
			First Named Inventor	Marth, Jamey D.	
			Art Unit	1635	
			Examiner Name	Zara, Jane J.	
Sheet	3	of		Attorney Docket Number	19452A-000320US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear


FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	BAUM, Linda G. et al.; "Human Thymic Epithelial Cells Express an Endogenous Lectin, Galectin-1, which Binds to Core 2 O-Glycans on Thymocytes and T Lymphoblastoid Cells"; 1995, <u>J. Exp. Med.</u> , Vol. 181, pp. 877-887.	
	AB	BIERHUIZEN, Marti F.A. et al.; "Expression cloning of a cDNA encoding UDP-GlcNAc:Gal β 1-3-GalNAc-R (GlcNAc to GalNAc) β 1-6GlcNAc transferase by gene transfer into CHO cells expressing polyoma Large tumor antigen"; 1992, <u>Proc. Natl. Acad. Sci.</u> , Vol. 89, pp. 9326-9330.	
	AC	BROCKHAUSEN, I. et al.; "Biosynthesis of O-Glycans in Leukocytes from Normal Donors and from Patients with Leukemia: Increase in O-Glycan Core 2 UDP-GlcNAc:Gal β 3GalNAc α -R (GlcNAc to GalNAc) β (1-6)-N-Acetylglucosaminyltransferase in Leukemic Cells" 1991, <u>Cancer Research</u> , Vol. 51, pp. 1257-1263.	
	AD	FOX, Robert I. et al.; "A Novel Cell Surface Antigen (T305) Found in Increased Frequency on Acute Leukemia Cells and in Autoimmune Disease States"; 1983, <u>The Journal of Immunology</u> , Vol. 131, No. 2, pp. 762-767.	
	AE	HIGGINS, Elizabeth A. et al.; "Aberrant O-Linked Oligosaccharide Biosynthesis in Lymphocytes and Platelets from Patients with the Wiskott-Aldrich Syndrome"; 1991, <u>The Journal of Biological Chemistry</u> , Vol. 266, No. 10, pp. 6280-6290.	
	AF	KUMAR, Ravindra et al.; "Core2 β -1,6-N-Acetylglucosaminyltransferase Enzyme Activity Is Critical for P-Selectin Glycoprotein Ligand-1 Binding to P-Selectin"; 1988, <u>Blood</u> , Vol. 88, No. 10, pp. 3872-3879.	
	AG	LASKY, Laurence A.; "Selectin-Carbohydrate Interactions and the Initiation of the Inflammatory Response"; 1995, <u>Annu. Rev. Biochem.</u> , Vol. 64, pp. 113-139.	
	AH	LOWE, John B.; "Selectin ligands, leukocyte trafficking, and fucosyltransferase genes"; 1997, <u>Kidney International</u> , Vol. 51, pp. 1418-1426.	
	AI	LOWE, John B. et al.; "Perspectives Series: Cell Adhesion in Vascular Biology"; 1997, <u>J. Clin. Invest.</u> , Vol. 99, No. 5, pp. 822-826.	
	AJ	MALY, Petr et al.; "The α (1,3) Fucosyltransferase Fuc-TVII Controls Leukocyte Trafficking through an Essential Role in L-, E-, and P-selection Ligand Biosynthesis"; 1996, <u>Cell</u> , Vol. 86, pp. 643-653.	
	AK	PILLER, Friedrich et al.; "Altered O-Glycan Synthesis in Lymphocytes from Patients with Wiskott-Aldrich Syndrome"; 1991, <u>J. Exp. Med.</u> , Vol. 173, pp. 1501-1510.	
	AL	PILLER, Friedrich et al.; "Human T-lymphocyte Activation Is Associated with Changes in O-Glycan Biosynthesis" 1991, <u>The Journal of Biological Chemistry</u> , Vol. 263, No. 29, pp. 15146-15150.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/856,391	
			Filing Date	January 7, 2002	
			First Named Inventor	Marth, Jamey D.	
			Art Unit	1635	
			Examiner Name	Zara, Jane J.	
Sheet	4	of		Attorney Docket Number	19452A-000320US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
NON PATENT LITERATURE DOCUMENTS								
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						T ²
	AM	SAITOH, Osamu et al.; "T-Lymphocytic Leukemia Expresses Complex, Branched O-Linked Oligosaccharides on a Major Sialoglycoprotein, Leukosialin"; 1991, <u>Blood</u> , Vol. 77, No. 7, pp. 1491-1499.						
	AN	SPRINGER, Timothy A.; "Traffic Signals on Endothelium for Lymphocyte Recirculation and Leukocyte Emigration"; 1995, <u>Annu. Rev. Physiol.</u> , Vol. 57, pp. 827-872.						
	AO	TSUBOI, Shigeru et al.; "Branched O-linked oligosaccharides ectopically expressed in transgenic mice reduce primary T-cell immune responses"; 1997, <u>The EMBO Journal</u> , Vol. 16, No. 21, pp. 6364-6373.						
	AP	WILLIAMS, David et al.; "Mucin Synthesis: I. Detection in Canine Submaxillary Glands of an N-Acetylglucosaminyltransferase which acts on Mucin Substrates"; 1980, <u>The Journal of Biological Chemistry</u> , Vol. 255, No. 23, pp. 11247-11252.						

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.